Alnylam Pharmaceuticals Inc’s filing revealed that its Chief Executive Officer Greenstreet Yvonne unloaded Company’s shares for reported $9.63 million on May 30 ’25. In the deal valued at $304.39 per share,31,640 shares were sold. As a result of this transaction, Greenstreet Yvonne now holds 48,948 shares worth roughly $20.54 million.
Then, Greenstreet Yvonne sold 19,297 shares, generating $5,904,882 in total proceeds. Upon selling the shares at $306.00, the Chief Executive Officer now owns 48,948 shares.
Before that, Greenstreet Yvonne bought 19,297 shares. Alnylam Pharmaceuticals Inc shares valued at $5,848,824 were divested by the Officer at a price of $303.10 per share.
Wolfe Research upgraded its Alnylam Pharmaceuticals Inc [ALNY] rating to a Peer perform from a an Underperform in a research note published recently. A number of analysts have revised their coverage, including Oppenheimer’s analysts, who increased its forecast for the stock in early August from “a Perform” to “an Outperform”. Truist started covering the stock on July 21, 2025. It rated ALNY as “a Buy”.
Price Performance Review of ALNY
On Monday, Alnylam Pharmaceuticals Inc [NASDAQ:ALNY] saw its stock jump 4.42% to $419.55. Over the last five days, the stock has gained 29.18%. Alnylam Pharmaceuticals Inc shares have risen nearly 76.68% since the year began. Nevertheless, the stocks have risen 78.30% over the past one year.
How much short interest is there in Alnylam Pharmaceuticals Inc?
A steep rise in short interest was recorded in Alnylam Pharmaceuticals Inc stocks on 2025-07-15, growing by 3658.0 shares to a total of 3.38 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 3.38 million shares. There was a rise of 0.11%, which implies that there is a positive sentiment for the stock.
